NCT00096629View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Kidney Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Kidney Cancer
Interventions
BIOLOGICAL

human prostate-specific membrane antigen plasmid DNA vaccine

BIOLOGICAL

mouse prostate-specific membrane antigen plasmid DNA vaccine

Trial Locations (1)

10021

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00096629 - Vaccine Therapy in Treating Patients With Kidney Cancer | Biotech Hunter | Biotech Hunter